Serum Sema3A Is in a Weak Positive Association With Bone Formation Marker Osteocalcin But Not Related to Bone Mineral Densities in Postmenopausal Women

Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 99; no. 12; pp. E2504 - E2509
Main Authors Liu, Dong-mei, Lu, Nan, Zhao, Lin, Zhang, Min-jia, Tao, Bei, Xuan, Yan, Sun, Li-hao, Zhao, Hong-yan, Wang, Wei-qing, Liu, Jian-min, Ning, Guang
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.12.2014
Copyright by The Endocrine Society
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.Design, Setting, and Participants:This was a cross-sectional study involving 1012 pre- and postmenopausal women.Main Outcome Measures:Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.Results:In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1–4 BMDs, and age were determinants of Ocn (adjusted R2 for the model = 0.532, P < .001) .Conclusions:The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures.
AbstractList Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.Design, Setting, and Participants:This was a cross-sectional study involving 1012 pre- and postmenopausal women.Main Outcome Measures:Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.Results:In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1–4 BMDs, and age were determinants of Ocn (adjusted R2 for the model = 0.532, P < .001) .Conclusions:The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures.
CONTEXT:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. OBJECTIVE:The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women. DESIGN, SETTING, AND PARTICIPANTS:This was a cross-sectional study involving 1012 pre- and postmenopausal women. MAIN OUTCOME MEASURES:Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants. RESULTS:In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1–4 BMDs, and age were determinants of Ocn (adjusted R for the model = 0.532, P < .001) . CONCLUSIONS:The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures.
The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women. This was a cross-sectional study involving 1012 pre- and postmenopausal women. Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants. In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1-4 BMDs, and age were determinants of Ocn (adjusted R(2) for the model = 0.532, P < .001) . The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures.
The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.CONTEXTThe chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.The aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.OBJECTIVEThe aim of the study was to investigate the associations between serum Sema3A, bone biochemical markers, and bone mineral densities (BMDs) in women.This was a cross-sectional study involving 1012 pre- and postmenopausal women.DESIGN, SETTING, AND PARTICIPANTSThis was a cross-sectional study involving 1012 pre- and postmenopausal women.Fasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.MAIN OUTCOME MEASURESFasting serum Sema3A, osteocalcin (Ocn), and cross-linked C-telopeptide of type 1 collagen were measured. Dual-energy X-ray absorptiometry was performed to determine the BMDs at the lumbar spine and femoral neck. History of osteoporotic fractures was reported by the participants.In postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1-4 BMDs, and age were determinants of Ocn (adjusted R(2) for the model = 0.532, P < .001) .RESULTSIn postmenopausal women (n = 860), a significant positive association between Sema3A and Ocn levels was demonstrated (r = 0.077, P = 0.025) when age was adjusted. The serum Ocn level was significantly higher in the fourth quartile of serum Sema3A as compared with the first quartile (21.09 ± 0.56 ng/mL vs 19.45 ± 0.44 ng/mL, P = .018). Serum Sema3A concentrations were similar in subjects with normal BMD, osteopenia or osteoporosis, and those with and without osteoporotic fractures. Multivariate stepwise regression analysis revealed that cross-linked C-telopeptide of type 1 collagen, body mass index, creatinine, Sema3A, L1-4 BMDs, and age were determinants of Ocn (adjusted R(2) for the model = 0.532, P < .001) .The positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures.CONCLUSIONSThe positive correlation between Sema3A and bone formation marker Ocn revealed in this human study partly supports the recently findings in mice studies. However, the general effects of Sema3A on bone metabolism are weak and not clear as evidenced by lack of association between this parameter and BMDs and osteoporotic fractures.
Author Zhao, Hong-yan
Sun, Li-hao
Lu, Nan
Liu, Dong-mei
Tao, Bei
Xuan, Yan
Wang, Wei-qing
Liu, Jian-min
Zhang, Min-jia
Zhao, Lin
Ning, Guang
AuthorAffiliation Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
AuthorAffiliation_xml – name: Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
Author_xml – sequence: 1
  givenname: Dong-mei
  surname: Liu
  fullname: Liu, Dong-mei
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 2
  givenname: Nan
  surname: Lu
  fullname: Lu, Nan
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 3
  givenname: Lin
  surname: Zhao
  fullname: Zhao, Lin
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 4
  givenname: Min-jia
  surname: Zhang
  fullname: Zhang, Min-jia
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 5
  givenname: Bei
  surname: Tao
  fullname: Tao, Bei
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 6
  givenname: Yan
  surname: Xuan
  fullname: Xuan, Yan
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 7
  givenname: Li-hao
  surname: Sun
  fullname: Sun, Li-hao
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 8
  givenname: Hong-yan
  surname: Zhao
  fullname: Zhao, Hong-yan
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 9
  givenname: Wei-qing
  surname: Wang
  fullname: Wang, Wei-qing
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 10
  givenname: Jian-min
  surname: Liu
  fullname: Liu, Jian-min
  email: liujianmin@medmail.com.cn
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
– sequence: 11
  givenname: Guang
  surname: Ning
  fullname: Ning, Guang
  email: guangning@medmail.com.cn
  organization: 1Department of Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China 200025
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25050899$$D View this record in MEDLINE/PubMed
BookMark eNp1kkFvFCEUx4mpsdvqzbMh8dAenAoMDOW4rVabtNZYzXojLPMmy-7MsALTxk_i15XZaS9NSkLIg9___17e4wDt9b4HhN5SckIZJR_X9oQRygvKefkCzajiopBUyT00I4TRQkn2ex8dxLgmGeOifIX2mSCCnCo1Q_9uIQwdvoXOlHN8GbHrscELMBv83UeX3B3geYzeOpOc7_HCpRU-yxXgCx-66e7ahA0EfBMTeGtamy3OhoS_-YR_QGsS1Dj5SXTtegimxZ-gH81hly8nSh30fmuGmN8WPgev0cvGtBHePJyH6NfF55_nX4urmy-X5_OrwpaqUgVQZjmtSGMkyJpQJeplVZekASmapaCNUYrVVFhpmqWsLQCplCI11LCklaDlITqefLfB_xkgJt25aKFtTQ9-iJpWJWcya1hG3z9B134Ifa5Ol7TivCKMqUy9e6CGZQe13gbXmfBXP7Y8A2wCbPAxBmi0dWnXyBSMazUlepyrXls9zlWPc82iD09Ej77P4HzC732bIMRNO9xD0CswbVppkhev5GkxCijLUZG3GEs7mmR-2D6XYPfPyv9Q8b9Y
CitedBy_id crossref_primary_10_1016_j_cmet_2018_12_021
crossref_primary_10_1007_s00018_018_2981_y
crossref_primary_10_3389_fendo_2022_1014431
crossref_primary_10_12998_wjcc_v7_i20_3310
crossref_primary_10_1016_j_mce_2015_09_009
crossref_primary_10_1016_j_biopha_2021_111321
crossref_primary_10_1038_nutd_2017_6
crossref_primary_10_2139_ssrn_4162722
crossref_primary_10_1016_j_bone_2018_06_003
crossref_primary_10_1155_2018_2318386
crossref_primary_10_1155_2019_2506463
crossref_primary_10_1007_s00223_025_01350_4
crossref_primary_10_1177_00220345241231777
crossref_primary_10_1016_j_prmcm_2022_100079
ContentType Journal Article
Copyright Copyright © 2014 by the Endocrine Society 2014
Copyright © 2014 by The Endocrine Society
Copyright © 2014 by the Endocrine Society
Copyright_xml – notice: Copyright © 2014 by the Endocrine Society 2014
– notice: Copyright © 2014 by The Endocrine Society
– notice: Copyright © 2014 by the Endocrine Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TM
H94
K9.
7X8
DOI 10.1210/jc.2014-1443
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList

AIDS and Cancer Research Abstracts
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage E2509
ExternalDocumentID 25050899
10_1210_jc_2014_1443
00004678-201412000-00059
10.1210/jc.2014-1443
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.XZ
08P
0R~
18M
1TH
29K
2WC
34G
354
39C
4.4
48X
53G
5GY
5RS
5YH
8F7
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
ABBLC
ABDFA
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AEWNT
AFCHL
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AGINJ
AGKRT
AGQXC
AGUTN
AHMBA
AHMMS
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
ARIXL
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BSWAC
BTRTY
C45
CDBKE
CS3
D-I
DAKXR
DIK
E3Z
EBS
EJD
EMOBN
ENERS
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
HZ~
H~9
KBUDW
KOP
KQ8
KSI
KSN
L7B
M5~
MHKGH
MJL
N9A
NLBLG
NOMLY
NOYVH
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
REU
ROX
ROZ
TEORI
TJX
TLC
TR2
TWZ
VVN
W8F
WOQ
X7M
YBU
YFH
YHG
YOC
YSK
ZY1
~02
~H1
.GJ
3O-
7X7
88E
8FI
8FJ
AAJQQ
AAKAS
AAPGJ
AAQQT
AAUQX
AAWDT
AAYJJ
ABDPE
ABUWG
ABXZS
ACFRR
ACVCV
ACZBC
ADMTO
ADNBA
ADZCM
AEMQT
AEOTA
AERZD
AFFNX
AFFQV
AFKRA
AFYAG
AGMDO
AGORE
AHGBF
AI.
AJBYB
AJDVS
ALXQX
APJGH
AQDSO
AQKUS
AVNTJ
BENPR
BPHCQ
BVXVI
CCPQU
EIHJH
FEDTE
FYUFA
HMCUK
HVGLF
IAO
IHR
INH
ITC
J5H
M1P
MBLQV
N4W
NU-
OBFPC
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
TMA
UKHRP
VH1
WHG
X52
ZGI
ZXP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TM
H94
K9.
7X8
ID FETCH-LOGICAL-c3969-e12c4160fa7e7d0195db6d30fe75fb51fa992d15c7afb7dcee06990dedeb16513
ISSN 0021-972X
1945-7197
IngestDate Fri Jul 11 16:09:11 EDT 2025
Mon Jun 30 12:42:00 EDT 2025
Thu Apr 03 07:10:57 EDT 2025
Tue Jul 01 01:10:32 EDT 2025
Thu Apr 24 23:12:50 EDT 2025
Fri May 16 03:43:26 EDT 2025
Fri Feb 07 10:35:39 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3969-e12c4160fa7e7d0195db6d30fe75fb51fa992d15c7afb7dcee06990dedeb16513
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 25050899
PQID 3164460229
PQPubID 2046206
ParticipantIDs proquest_miscellaneous_1634276992
proquest_journals_3164460229
pubmed_primary_25050899
crossref_citationtrail_10_1210_jc_2014_1443
crossref_primary_10_1210_jc_2014_1443
wolterskluwer_health_00004678-201412000-00059
oup_primary_10_1210_jc_2014-1443
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20141201
2014-December
2014-12-00
2014-Dec
PublicationDateYYYYMMDD 2014-12-01
PublicationDate_xml – month: 12
  year: 2014
  text: 20141201
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2014
Publisher Oxford University Press
Copyright by The Endocrine Society
Publisher_xml – name: Oxford University Press
– name: Copyright by The Endocrine Society
SSID ssj0014453
Score 2.2373157
Snippet Context:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.Objective:The...
CONTEXT:The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. OBJECTIVE:The...
The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described. The aim of the study...
The chemorepellent semaphorin-3A (Sema3A) was shown to favor bone metabolism in mice, but its bone effects in humans are not described.CONTEXTThe...
SourceID proquest
pubmed
crossref
wolterskluwer
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage E2504
SubjectTerms Absorptiometry, Photon
Adult
Aged
Aged, 80 and over
Biochemical markers
Biomarkers - blood
Body mass index
Bone Density - physiology
Bone growth
Bone turnover
Collagen
Collagen Type I - blood
Creatinine
Creatinine - blood
Cross-Sectional Studies
Dual energy X-ray absorptiometry
Female
Fractures
Humans
Metabolism
Middle Aged
Osteocalcin
Osteocalcin - blood
Osteogenesis
Osteogenesis - physiology
Osteopenia
Osteoporosis
Post-menopause
Postmenopause - physiology
Semaphorin-3A - blood
Semaphorins
Spine (lumbar)
Young Adult
Title Serum Sema3A Is in a Weak Positive Association With Bone Formation Marker Osteocalcin But Not Related to Bone Mineral Densities in Postmenopausal Women
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201412000-00059
https://www.ncbi.nlm.nih.gov/pubmed/25050899
https://www.proquest.com/docview/3164460229
https://www.proquest.com/docview/1634276992
Volume 99
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAIIe4UBjISPFVGuad55LJpA3W8bGJvkePYqN2aTEsiJP4IP4-_wjm2k7qjFZeXKE2dxMn5fG45F0JelWHsiViELBVBxKI4LFmmwFhJp3IaRyoEkYIO_dlRcnASfTyNT0ejn07UUtcWb8T3jXkl_0NVOAZ0xSzZf6DscFE4APtAX9gChWH7VzSGhd4tYbkvOdj1hzqylU--SH6GPXhNUJDz-oEDtJjcAGrlfp-yqHN15OXkMxAbpZqAS7zr2slR3Zo4OdBHQTvVJ83mukI1sKiq0XVY8X7Y7BcLjl_wrtG-96XNLVusYOhUpxgSMWVV1sCwqlUJqKVsAZDnfUlDDBKad0bHr76ypZwPhzsrFhynd239C7_5wWHSbDHnrnPDj64EimxJmnQZOkaYpLojO4gzw8OzKGapb8J-eyZvujD1YA4clr2HRdwc-Y-_s43CBaxjFC5Y-BJnGpn6UlfKdW8eeI1cD8COwRYbHw4_DZ-5osiWSbVPYTMzMK3KPXtNZ1rLw3TMoVvk9rcaIyyaM51g4ahJx3fJHWvf0LcGrPfISFb3yY2ZjeB4QH5ozFKDWXrY0HlFOUXM0h6z1MEsRcxShB8dMEsNZqmDWQqYpYBZajFL29qcZDFLB8zi_dYxSzVmH5KT_b3j9wfMNgdhIsySjEk_EGBMeIqnMi0x7bUskjL0lExjVcS-4lkWlH4sUq6KtARd0EtA8yplCdpJEvvhI7JTwUSeEMrLwONqmvpFrCKheFEoD3aVF8hwKjwxJpP-9efCVs7HBi7nOVrQQKx8IXIkVo7EGpPXw-gLUzFmyzgKlNw2hJkhuz2Zc7tUmzz0wYRJQPXOxuTl8DcIBfzSxytZd00ORlYUpPC8wZg8NvAYboQ2D37rHxO2hpfcJF7n2msAKizDafh95Yk4e_rn-T4jN1eLeJfstJedfA46e1u80Lj_BcKd6gE
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Sema3A+Is+in+a+Weak+Positive+Association+With+Bone+Formation+Marker+Osteocalcin+But+Not+Related+to+Bone+Mineral+Densities+in+Postmenopausal+Women&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Liu%2C+Dong-mei&rft.au=Lu%2C+Nan&rft.au=Zhao%2C+Lin&rft.au=Zhang%2C+Min-jia&rft.date=2014-12-01&rft.pub=Oxford+University+Press&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=99&rft.issue=12&rft.spage=E2504&rft.epage=E2509&rft_id=info:doi/10.1210%2Fjc.2014-1443&rft.externalDocID=10.1210%2Fjc.2014-1443
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon